Methylation level of Rap1GAP and the clinical significance in MDS

  • Authors:
    • Wen‑Jing Ding
    • Yi Yang
    • Zi‑Xing Chen
    • Yuan‑Yuan Wang
    • Wan‑Li Dong
    • Jian‑Nong Cen
    • Xiao‑Fei Qi
    • Feng Jiang
    • Su‑Ning Chen
  • View Affiliations

  • Published online on: September 26, 2018     https://doi.org/10.3892/ol.2018.9503
  • Pages: 7287-7294
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies on the pathogenesis of myelodysplastic syndrome (MDS) have identified multiple associated gene mutations, including mutations of tetmethylcytosinedioxygenase 2, isocitrate dehydrogenase [NADP(+)] 1 cytosolic, isocitrate dehydrogenase [NADP(+)] 2 mitochondrial and additional sex combs like 1 transcriptional regulator, all of which may be considered epigenetic regulators. Furthermore, mutations of RAS type GTPase family genes have been identified in 10‑15% patients with MDS. The authors' previous study on the gene expression profile of cluster of differentiation 34+ cells using microarray analysis identified elevated expression of RAP1GTPase activating protein 1 (Rap1GAP) in patients with MDS compared with that in non‑malignant blood diseases (NM) control group. To further investigate the mechanism of increased Rap1GAP expression, the methylation pattern of the promoter of this gene was determined in 86 patients with MDS (n=29), acute myeloid leukemia (AML) (n=31) or NM (n=26) using bisulfite‑specific polymerase chain reaction and DNA sequencing. The results demonstrated that the methylation of Rap1GAP occurred in all 29 patients with MDS at multiple CpG sites. The methylation level of Rap1GAP in patients with MDS was decreased compared with that in patients with NM. Significant differences at 4CpG sites (5,7,8 and 12) of Rap1GAP promoter were identified between MDS and NM. Furthermore, based on the present clinical records of the patient cohort, the methylation status of Rap1GAP promoter did not appear to be associated with the clinicopathological characteristics of patients with MDS, including age, gender and International Prognosis Score System. The difference in methylation level at CpG site 8 of Rap1GAP promoter was identified to be significantly increased in patients with MDS‑refractory anemia with ring sideroblasts compared with that in the MDS‑refractory cytopenia with multilineage dysplasia or MDS‑unclassified groups. The results of the present study suggest that patients with MDS exhibit a lower overall methylation level within Rap1GAP promoter compared with patients with NM or AML. In addition, the methylation level at the four identified CpG sites can distinguish between MDS and NM.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ding WJ, Yang Y, Chen ZX, Wang YY, Dong WL, Cen JN, Qi XF, Jiang F and Chen SN: Methylation level of Rap1GAP and the clinical significance in MDS. Oncol Lett 16: 7287-7294, 2018
APA
Ding, W., Yang, Y., Chen, Z., Wang, Y., Dong, W., Cen, J. ... Chen, S. (2018). Methylation level of Rap1GAP and the clinical significance in MDS. Oncology Letters, 16, 7287-7294. https://doi.org/10.3892/ol.2018.9503
MLA
Ding, W., Yang, Y., Chen, Z., Wang, Y., Dong, W., Cen, J., Qi, X., Jiang, F., Chen, S."Methylation level of Rap1GAP and the clinical significance in MDS". Oncology Letters 16.6 (2018): 7287-7294.
Chicago
Ding, W., Yang, Y., Chen, Z., Wang, Y., Dong, W., Cen, J., Qi, X., Jiang, F., Chen, S."Methylation level of Rap1GAP and the clinical significance in MDS". Oncology Letters 16, no. 6 (2018): 7287-7294. https://doi.org/10.3892/ol.2018.9503